Analyst Ratings For Kala Pharmaceuticals (NASDAQ:KALA)
Today, Wells Fargo & Co lowered its price target on Kala Pharmaceuticals (NASDAQ:KALA) to $19.00 per share.
Some recent analyst ratings include
- 12/22/2017-Wedbush Reiterated Rating of Outperform.
- 8/15/2017-Oppenheimer initiated coverage with a Outperform rating.
- 8/14/2017-Bank of America initiated coverage with a Buy rating.
- On 1/24/2018 Orbimed Advisors Llc, Major Shareholder, bought 64,637 with an average share price of $14.91 per share and the total transaction amounting to $963,737.67.
- On 1/22/2018 Orbimed Advisors Llc, Major Shareholder, bought 75,000 with an average share price of $14.98 per share and the total transaction amounting to $1,123,500.00.
- On 1/19/2018 Orbimed Advisors Llc, Major Shareholder, bought 74,931 with an average share price of $14.95 per share and the total transaction amounting to $1,120,218.45.
- On 1/12/2018 Orbimed Advisors Llc, Major Shareholder, bought 240,484 with an average share price of $13.28 per share and the total transaction amounting to $3,193,627.52.
- On 1/10/2018 Orbimed Advisors Llc, Major Shareholder, bought 170,338 with an average share price of $12.83 per share and the total transaction amounting to $2,185,436.54.
- On 7/25/2017 Longitude Capital Partners Ii,, Major Shareholder, bought 215,000 with an average share price of $15.00 per share and the total transaction amounting to $3,225,000.00.
- On 7/25/2017 Orbimed Advisors Llc, Insider, bought 319,333 with an average share price of $15.00 per share and the total transaction amounting to $4,789,995.00.
Recent Trading Activity for Kala Pharmaceuticals (NASDAQ:KALA)
Shares of Kala Pharmaceuticals closed the previous trading session at 14.95 up +0.03 0.20% with 15.638999938964844 shares trading hands.